849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ocifisertib Breast Cancer	Canadian Cancer Trials Group	P2	CC (43)
Onlife® Breast Cancer	Centre Georges Francois Leclerc	P2	CC (43)
Oxodotreotide Breast Cancer	RayzeBio, Inc.	P1/2	CC (43)
p2et Breast Cancer	Hospital Universitario San Ignacio	P2	CC (43)
Parstuzumab Breast Cancer	Henan Cancer Hospital	P2	CC (43)
PCS6422 Breast Cancer	Processa Pharmaceuticals	P2	CC (43)
Pembrolizuma Breast Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CC (43)
Penpulimab Breast Cancer	West China Hospital	P2	CC (43)
PF-0704091 Breast Cancer	Pfizer	P2	CC (43)
Pidnarulex Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
Pmd-026 Breast Cancer	Phoenix Molecular Designs	P1/2	CC (43)
Posaconazole Breast Cancer	Shandong Cancer Hospital and Institute	P2	CC (43)
Ptc-Pz Breast Cancer	Borstkanker Onderzoek Groep	P2	CC (43)
Pudexacianinium Chloride Breast Cancer	Astellas Pharma Inc	P2	CC (43)
Pyrrolidone Breast Cancer	Xijing Hospital	P2	CC (43)
qbs72s Breast Cancer	Stanford University	P2	CC (43)
qlc1401 Breast Cancer	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (43)
rc148 Breast Cancer	RemeGen Co., Ltd.	P2	CC (43)
(R)-Cetirizine Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CC (43)
Romiplostim Breast Cancer	Peking University People's Hospital	P2	CC (43)
Sapu003 Breast Cancer	SAPU NANO (US) LLC	P1	CC (43)
Sarilumab Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)
Selicrelumab Breast Cancer	Hoffmann-La Roche	P1/2	CC (43)
Serplulimab Breast Cancer	Xijing Hospital	P2	CC (43)
sh009 Breast Cancer	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P1	CC (43)
Shr-1167 Breast Cancer	Fudan University	P2	CC (43)
Shr-4602 Breast Cancer	Fudan University	P2	CC (43)
Shr-6209 Breast Cancer	Fudan University	P2	CC (43)
Shr-A1811:Pyrotinib Breast Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	CC (43)
Si-B003 Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CC (43)
Sleeping Beauty Transposed Pbl Breast Cancer	National Cancer Institute (NCI)	P2	CC (43)
Slv-154 Breast Cancer	Solve Therapeutics	P1	CC (43)
Surufatinib Breast Cancer	The First Affiliated Hospital of Zhengzhou University	P2	CC (43)
Tagolimumab Breast Cancer	Sun Yat-sen University	P2	CC (43)
Taletrectinib Breast Cancer	Megan Kruse, MD	P2	CC (43)
Tcr Transduced T-Cells Breast Cancer	National Cancer Institute (NCI)	P2	CC (43)
tfx06 Breast Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (43)
Tinengotinib Breast Cancer	TransThera Sciences (Nanjing), Inc.	P2	CC (43)
tn-1 Breast Cancer	Nagoya City University	P2	CC (43)
Tobemstomig Breast Cancer	Hoffmann-La Roche	P2	CC (43)
Tolinapant Breast Cancer	National Cancer Institute (NCI)	P1	CC (43)
tqb2868 Breast Cancer	Fudan University	P2	CC (43)
TQB2930 for injection Breast Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	CC (43)
tqb3909 Breast Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	CC (43)
Trastuzumab Sc Breast Cancer	Peking University Cancer Hospital & Institute	P2	CC (43)
Tuvonralimab Breast Cancer	Anhui Provincial Cancer Hospital	P2	CC (43)
Ucmym802 Breast Cancer	UTC Therapeutics Inc.	P1	CC (43)
Ursodeoxycholic Acid Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CC (43)
Vericiguat Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (43)
vv1 Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (43)

Showing 501 to 550 of 849 assets

PreviousPage 11 of 17Next